^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Cutaneous T-cell Lymphoma
    Drug:KT-333 (STAT3 protein degrader)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    GlobeNewswire
    Title:

    Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma

    Published date:
    09/18/2023
    Excerpt:
    Kymera Therapeutics...announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to KT-333 for the treatment of R/R Cutaneous T-cell Lymphoma (CTCL) and R/R Peripheral T-cell Lymphoma (PTCL).